Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.

Watts, Justin M; Baer, Maria R; Yang, Jay; Prebet, Thomas; Lee, Sangmin; Schiller, Gary J; Dinner, Shira N; Pigneux, Arnaud; Montesinos, Pau; Wang, Eunice S; Seiter, Karen P; Wei, Andrew H; De Botton, Stephane; Arnan, Montserrat; Donnellan, Will; Schwarer, Anthony P; Récher, Christian; Jonas, Brian A; Ferrell, P Brent; Marzac, Christophe; Kelly, Patrick; Sweeney, Jennifer; Forsyth, Sanjeev; Guichard, Sylvie M; Brevard, Julie; Henrick, Patrick; Mohamed, Hesham; Cortes, Jorge E

doi:10.1016/S2352-3026(22)00292-7

Title

Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.

Publication Date

2023-01

Author(s)

Watts, Justin M

Baer, Maria R

Yang, Jay

Prebet, Thomas

Lee, Sangmin

Schiller, Gary J

Dinner, Shira N

Pigneux, Arnaud

Montesinos, Pau

Wang, Eunice S

Seiter, Karen P

Wei, Andrew H

De Botton, Stephane

Arnan, Montserrat

Donnellan, Will

Schwarer, Anthony P

Récher, Christian

Jonas, Brian A

Ferrell, P Brent

Marzac, Christophe

Kelly, Patrick

Sweeney, Jennifer

Forsyth, Sanjeev

Guichard, Sylvie M

Brevard, Julie

Henrick, Patrick

Mohamed, Hesham

Cortes, Jorge E

Type of document

Journal Article

OrcId

#PLACEHOLDER_PARENT_METADATA_VALUE#

DOI

10.1016/S2352-3026(22)00292-7

Abstract

Olutasidenib (FT-2102) is a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase 1 (IDH1). The aims for phase 1 of this phase 1/2 study were to assess the safety, pharmacokinetics, pharmacodynamics, and clinical activity of olutasidenib, as monotherapy or in combination with azacitidine, in patients with acute myeloid leukaemia or myelodysplastic syndrome, harbouring mutant IDH1.

Link

link

Citation

The Lancet. Haematology 2023; 10(1)

Jornal Title

The Lancet. Haematology

ISSN

2352-3026

Austin Health

Files: